Reduction in C-reactive protein through cardiac rehabilitation and exercise training

Journal of the American College of Cardiology

Volumn 43, Issue 6, 2004, Pages 1056-1061

  Milani, Richard V ^a   Lavie, Carl J ^a   Mehra, Mandeep R ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

ACS; Acute coronary syndromes; BMI; Body mass index; CHD; Coronary heart disease; High sensitivity C reactive protein; HSCRP; Oxygen consumption; PCI; Percutaneous coronary intervention; VO2

Indexed keywords

C REACTIVE PROTEIN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID;

ADULT; AGED; ARTICLE; BODY FAT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; EXERCISE; FEMALE; HEART REHABILITATION; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; OBESITY; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; TRAINING; WEIGHT REDUCTION;

AGED; BLOOD GLUCOSE; BODY MASS INDEX; C-REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; EXERCISE; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 1542603465     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.10.041     Document Type: Article

References (52)

1. Vorchheimer D.A., Fuster V. Inflammatory markers in coronary artery disease. Let prevention douse the flames. JAMA. 286:2001;2154-2156.
2. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 340:1999;115-126.
3. Ridker P.M. High-sensitivity C-reactive protein. Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 103:2001;1813-1818.
4. Ridker P.M. Evaluating novel cardiovascular risk factors Can we better predict heart attacks? Ann Intern Med. 130:1999;933-937.
5. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 342:2000;836-843.
6. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 336:1997;973-979.
7. Liuzzo G., Biasucci L.M., Gallimore J.R., et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 331:1994;417-424.
8. Biasucci L.M., Liuzzo G., Grillo R.L., et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation. 99:1999;855-860.
9. Lindahl B., Toss H., Siegbahn A., Venge P., Wallentin L., FRISC Study Group. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary disease. N Engl J Med. 343:2000;1139-1147.
10. Haverkate F., Thompson S.G., Pyke S.D., Gallimore J.R., Pepys M.B., European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 349:1997;462-466.
11. Cholesterol and Recurrent Events (CARE) Investigators, Ridker P.M., Rifai N., Pfeffer M.A., et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 98:1998;839-844.
12. Ferreirós E.R., Boissonnet C.P., Pizarro R., et al. Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation. 100:1999;1958-1963.
13. Cook D.G., Mendall M.A., Whincup P.H., et al. C-reactive protein concentration in children Relationship to adiposity and other cardiovascular risk factors. Atherosclerosis. 149:2000;139-150.
14. Rader D. Inflammatory markers of coronary risk. N Engl J Med. 343:2000;1179-1182.
15. Cushman M., Meilahn E.N., Psaty B.M., Kuller L.H., Dobs A.S., Tracy R.P. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol. 19:1999;893-899.
16. Yudkin J.S., Stehouwer C.D., Emeis J.J., Coppack S.W. C-reactive protein in healthy subjects Associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 19:1999;972-978.
17. Festa A., D'Agostino R. Jr., Howard G., Mykkanen L., Tracy R.P., Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome The insulin resistance atherosclerosis study (iras). Circulation. 102:2000;42-47.
18. Milani R.V., Lavie C.J. Prevalence and profile of metabolic syndrome in patients following acute coronary events and effects of therapeutic lifestyle change with cardiac rehabilitation. Am J Cardiol. 92:2003;50-54.
19. Tchernof A., Nolan A., Sites C.K., Ades P.A., Poehlman E.T. Weight loss reduced C-reactive protein levels in obese postmenopausal women. Circulation. 105:2002;564-569.
20. Albert M.A., Danielson E., Rifai N., Ridker P.M., PRINCE Investigators. Effect of statin therapy on C-reactive protein levels The pravastatin inflammation/crp evaluation (prince): a randomized trial and cohort study. JAMA. 286:2001;64-70.
21. Musial J., Undas A., Gajewski P., Jankowski M., Sydor W., Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol. 77:2001;247-253.
22. Ridker P.M., Rifai N., Lowenthal S.P. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 103:2001;1191-1193.
23. Lavie C.J., Milani R.V., Littman A.B. Benefits of cardiac rehabilitation and exercise training in secondary coronary prevention in the elderly. J Am Coll Cardiol. 22:1993;678-683.
24. Milani R.V., Lavie C.J., Cassidy M.M. Effects of cardiac rehabilitation and exercise training programs on depression in patients after major coronary events. Am Heart J. 132:1996;726-732.
25. Milani R.V., Lavie C.J. Behavioral differences and effects of cardiac rehabilitation in diabetic patients following cardiac events. Am J Med. 17:1996;72-80.
26. Lavie C.J., Milani R.V. Effects of cardiac rehabilitation, exercise training and weight reduction on exercise capacity, coronary risk factors, behavioral characteristics and quality of life in obese coronary patients. Am J Cardiol. 79:1997;397-401.
27. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
28. de Lorgeril M., Renaud S., Mamelle N., et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet. 343:1994;1454-1459.
29. Rifai N., Tracy R.P., Ridker P.M. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 45:1999;2136-2141.
30. Jackson A.S., Pollock M.L. Practical assessment of body composition. Physician Sports Med. 13:1985;76-90.
31. Milani R.V., Lavie C.J. The effects of body composition changes to observed improvements in cardiopulmonary parameters after exercise training with cardiac rehabilitation. Chest. 113:1998;599-601.
32. Zwaka T.P., Hombach V., Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages Implications for atherosclerosis. Circulation. 103:2001;1194-1197.
33. Torzewski M., Rist C., Mortensen R.F., et al. C-reactive protein in the arterial intima Role of c-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol. 20:2000;2094-2099.
34. Pasceri V., Willerson J.T., Yeh E.T.H. Direct proinflammatory effects of C-reactive protein on human endothelial cells. Circulation. 102:2000;2165-2168.
35. Bhakdi S., Torzewski M., Klouche M., Hemmes M. Complement and atherogenesis Binding of crp to degraded, nonoxidized ldl enhances complement activation. Arterioscler Thromb Vasc Biol. 19:1999;2348-2354.
36. Fichtlscherer S., Rosenberger G., Walter D.H., Breuer S., Dimmeler S., Zeiher A.M. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation. 102:2000;1000-1006.
37. Mendall M.A., Strachan D.P., Butland B.K., et al. C-reactive protein Relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J. 21:2000;1584-1590.
38. Verheggen P.W., de Maat M.P., Cats V.M., et al. Inflammatory status as the main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function. Eur Heart J. 20:1990;567-574.
39. Lindmark E., Diderholm E., Wallentin L., Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease Effects of an early invasive or noninvasive strategy. JAMA. 286:2001;2107-2113.
40. Ridker P.M., Rifai N., Rose L., Burning J.E., Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 347:2002;1557-1565.
41. Kwak B., Mulhaupt F., Myit S., Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 6:2000;1399-1402.
42. Grundy S.M., Vega G.L., McGovern M.E., et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia with type 2 diabetes Results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med. 162:2002;1568-1576.
43. Ballantyne C.M., Houri J., Notarbartolo A., et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia A prospective, randomized, double-blind trial. Circulation. 107:2003;2409-2415.
44. Rizos E., Kostoula A., Elisaf M., Mikhailidis D.P. Effect of ciprofibrate on C-reactive protein and fibrinogen levels. Angiology. 53:2002;273-277.
45. Landin K., Stigendal L., Eriksson E., et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism. 39:1990;1044-1048.
46. Campos S.P., Baumann H. Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes. Mol Cell Biol. 12:1992;1789-1797.
47. Yudkin J.S., Kumari M., Humphries S.E., Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease Is interleukin-6 the link? Atherosclerosis. 148:2000;209-214.
48. Endres S., Ghorbani R., Kelley V.E., et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med. 320:1989;265-271.
49. Leaf A., Kang J.X. Omega-3 fatty acids and cardiovascular disease. World Rev Nutr Diet. 89:2001;161-172.
50. Grimm H., Mayer K., Mayser P., Eigenbrodt E. Regulatory potential of n-3 fatty acids in immunological and inflammatory processes. Br J Nutr. 87:(Suppl 1):2002;S59-S67.
51. Abramson J.L., Vaccarino V. Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults. Arch Intern Med. 162:2002;1286-1292.
52. Mattusch F., Dufaux B., Heine O., Mertens I., Rost R. Reduction of the plasma concentration of C-reactive protein following 9 months of endurance training. Int J Sports Med. 21:2000;21-24.